How Long Has Mounjaro Been Used, and What Does That History Tell Us?

Step 1: The early research years (roughly 2017–2021)

Tirzepatide began its formal clinical life in phase 1 and phase 2 trials designed to establish safety, tolerability and dose ranges. These were diabetes-focused studies first, because the GIP and GLP-1 receptor pathways tirzepatide targets are central to blood-sugar regulation. Researchers noticed something else too: participants were losing substantial body weight. That observation seeded what would become the SURMOUNT weight-management programme.

If you want to trace this early research in detail, the testing history of tirzepatide covers the phase-by-phase progression. The short version: by the time SURMOUNT-1 began recruiting, tirzepatide already had years of human safety data behind it. That context matters when patients ask how new this medicine really is.

It is worth doing one quick check yourself: look up any online pharmacy on the GPhC register before you hand over any medical information. A legitimate pharmacy will appear within seconds. That habit alone filters out a significant number of illegitimate sellers.

Step 2: The SURMOUNT trials and regulatory approval (2021–2023)

SURMOUNT-1, the pivotal weight-management trial, enrolled 2,539 adults with obesity or overweight and at least one weight-related condition. Over 72 weeks, participants at the highest dose saw an average body-weight reduction of around 20–21%, a result published in the New England Journal of Medicine and subsequently reviewed by regulators on both sides of the Atlantic.

The MHRA granted Mounjaro a UK licence for type 2 diabetes management in 2022, then extended that licence to weight management in November 2023. That sequence matters: by the time weight-management prescriptions began in the UK, the medicine had already been in patients' hands for over a year through the diabetes indication. Real-world tolerability data were building alongside the trial results.

For readers who are curious how long Mounjaro has been commercially available across different countries, that timeline varies; the UK launch for weight management sits at late 2023.

Step 3: NICE appraisal, NHS rollout and what the evidence looks like now (2024–present)

In December 2024, NICE published Technology Appraisal 1026, recommending tirzepatide for adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower BMI thresholds applying for some ethnic backgrounds under the full NICE TA1026 guidance. That appraisal drew on the entire SURMOUNT programme, meaning regulators had access to data from thousands of adults across multiple trials before making the recommendation.

The NHS is rolling out access in phases through 2025 and beyond, with criteria tightening progressively as more clinical capacity comes online. Private routes (through GPhC-registered online pharmacies like ours) have been active since late 2023, subject to full clinical assessment for each patient.

By mid-2026, tirzepatide has been in prescribers' hands in the UK for over two and a half years, and the post-marketing evidence pool continues to grow. How quickly Mounjaro begins to produce results is a separate question from how long it has existed, but the longer history gives clinicians a much richer picture of what to expect.

What this timeline means for anyone starting treatment today

Starting in 2024 or 2025 is, in one sense, a better-evidenced starting point than 2023 was. Prescribers now have the SURMOUNT data, the NICE appraisal, two-plus years of UK real-world experience, and emerging head-to-head comparison data against semaglutide. The medicine is not brand new in the way it once was.

That said, tirzepatide still carries a Black Triangle (▼) designation from the MHRA, meaning enhanced monitoring continues as post-marketing data accumulate. This is standard for recently licensed medicines and does not imply concern, it reflects a commitment to ongoing evidence review. Our clinical team follows MHRA updates as standard practice.

The broader history of the active ingredient is covered on the tirzepatide history page, including the parallel diabetes programme that informed so much of the weight-management development. For context on how long Mounjaro has been used specifically in diabetes care, that lane has a longer track record than the weight-management one. And if you want to understand the broader market history of the product, that page covers international timelines too.

If you are weighing up whether to start treatment now, the free consultation at nume is the right next step. A GPhC-registered prescriber (a real clinician, not software) will review your answers the same day and assess whether tirzepatide is right for you.